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Background: The M-type phospholipase A2 receptor (PLA2R1) plays a crucial role in several signaling pathways and
may act as tumor-suppressor. This study examined the expression and methylation of the PLA2R1 gene in Jurkat and
U937 leukemic cell lines and its methylation in patients with myelodysplastic syndrome (MDS) or acute leukemia.
Methods: Sites of methylation of the PLA2R1 locus were identified by sequencing bisulfite-modified DNA fragments.
Methylation specific-high resolution melting (MS-HRM) analysis was then carried out to quantify PLA2R1 methylation at
5`-CpG sites identified with differences in methylation between healthy control subjects and leukemic patients using
sequencing of bisulfite-modified genomic DNA.
Results: Expression of PLA2R1 was found to be completely down-regulated in Jurkat and U937 cells, accompanied by
complete methylation of PLA2R1 promoter and down-stream regions; PLA2R1 was re-expressed after exposure of cells
to 5-aza-2´-deoxycytidine. MS-HRM analysis of the PLA2R1 locus in patients with different types of leukemia indicated
an average methylation of 28.9% ± 17.8%, compared to less than 9% in control subjects. In MDS patients the extent of
PLA2R1 methylation significantly increased with disease risk. Furthermore, measurements of PLA2R1 methylation
appeared useful for predicting responsiveness to the methyltransferase inhibitor, azacitidine, as a pre-emptive
treatment to avoid hematological relapse in patients with high-risk MDS or acute myeloid leukemia.
Conclusions: The study shows for the first time that PLA2R1 gene sequences are a target of hypermethylation in
leukemia, which may have pathophysiological relevance for disease evolution in MDS and leukemogenesis.
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Phospholipases A2 (sPLA2, phosphatide sn-2-acylhydro-
lases, EC 3.1.1.4) belong to the superfamily of phospholi-
pases that catalyze the hydrolysis of the sn-2 ester bond in
phospholipids generating free fatty acids and lysophospho-
lipids [1]. Both reaction products may function as bio-
active lipid mediators. In addition to functions dependent
on their enzymatic activities, the group of secreted PLA2s
can also act independently as receptor ligands. Most re-
cently, sPLA2-IB and sPLA2-IIA have been identified as
activators of different signaling pathways that are able to
trigger cellular responses, such as cell proliferation,
growth, differentiation and apoptosis [2-8].* Correspondence: Mario.Menschikowski@uniklinikum-dresden.de
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distribution, and reproduction in any mediumTo date, three types of potential binding sites for sPLA2
have been identified; the N (neuronal)-type receptor, the
M (muscle)-type receptor (PLA2R1), and integrins αvβ3
and α4β1. The N-type receptor is mainly expressed in
neuronal tissues and likely plays an important role in the
mediation of neurotoxic effects of sPLA2s [9]. However,
the binding affinities of sPLA2-IB and sPLA2-IIA to the
N-type PLA2 receptor are low [10]. The M-type sPLA2 re-
ceptor was first identified in skeletal muscle, but is also
expressed in other tissues [11]. The receptor has a high
homology to the mannose-type receptor of macrophages,
which is involved in the endocytosis of glycoproteins [12].
The M-type receptor is a type-1 180 kDa transmembrane
glycoprotein containing extracellularly a cystein-reach do-
main, a fibronectin type II domain and eight carbohydrate
recognition domains [10,13]. Recently, it was shown that
patients with idiopathic membraneous nephropathy haveCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Menschikowski et al. BMC Cancer 2012, 12:576 Page 2 of 10
http://www.biomedcentral.com/1471-2407/12/576antibodies against a conformation-dependent epitope in
PLA2R1 [14]. Moreover, a high binding affinity of sPLA2-
IIA to integrins of type αvβ3 and α4β1 was described in
monocytic cells [6].
In the current study we analyzed the expression of the
PLA2R1 in Jurkat and U937 leukemic cells and found for
the first time a re-expression of the receptor after expos-
ure of this cell lines to 5-aza-2´-deoxycytidine (5-aza-dC)
suggesting that epigenetic mechanisms are involved in the
regulation of this receptor. Based on this finding we fur-
ther examined the methylation of the PLA2R1 gene in
tumor cell lines and in bone marrow aspirates of myelo-
dysplastic syndrome (MDS) patients and compared the
methylation of the PLA2R1 gene in the peripheral blood
of leukemic patients with those of healthy control subjects.
Materials and methods
Blood collections
Peripheral EDTA-blood samples were derived from 32
leukemic patients (20 females and 12 males) and 52
healthy individuals (34 females and 18 males). Median
ages were 47.1 ± 28.6 years (range 2 to 78 years) in the
leukemic patient group and 32.6 ± 16.3 years (range 1 to
82 years) in the healthy group. In addition, bone marrow
aspirates were derived from 38 MDS patients (18 females
and 20 males) with different IPSS classifications (12
patients with low-risk, 13 with intermediate-1-risk, five
with intermediate-2-risk, and eight with high-risk classifi-
cations). Median ages were 68.8 ± 9.0 years (range 47 to
78 years) in the MDS patient group.
Furthermore, two EDTA-blood samples of 18 patients
with high-risk MDS or AML, which were included in the
clinical RELAZA trial [15] and who were treated with aza-
citidine (Vidaza; Celgene Corporation, Summit, NJ, USA;
75 mg/m2/day subcutaneously on days 1–7 of one course)
were received for measurements of PLA2R1 gene methy-
lation at the beginning and end of the treatment. Finally,
EDTA-blood samples of one patient (58 years old female)
with AML, FAB M2, were received for serial measure-
ments of PLA2R1 gene methylation. After allogeneic
hema-topoietic stem cell transplantation (HSCT) and with
minimal residual disease (MRD), the patient underwent 3
courses of azacitidine treatment (75 mg/m2/day subcuta-
neously on days 1–7 per one course).
All patients provided written informed consent for the
following studies and the use of the patient blood samples
was approved by the Ethical Board of the University Hos-
pital of Dresden. Patient demographics and disease char-
acteristics are summarized in Additional file 1: Table S1,
Additional file 2: Table S2 and Additional file 3: Table S3.
Culture cell lines and incubation
Jurkat (human T lymphocyte acute leukemia), U937
(human hystiocytic lymphoma), Bv173 (human B-cellprecursor leukemia), K-562 (human chronic myeloic
leukemia in blast crisis), OC1-AML3 (human acute mye-
loid leukemia), KG-1A (human acute myeloid leukemia)
and RPMI 8226 (human myeloma) cell lines were pur-
chased from the German Collection of Microorganisms
and Cell Cultures (DSMZ, Braunschweig, Germany). Cells
were cultured in standard cell medium RPMI-1640 sup-
plemented with 10% heat-inactivated fetal calf serum
(FCS), 2 mM L-glutamine, 100 U/ml penicillin, and
100 μg/ml streptomycin at 37°C in a humidified atmos-
phere of 5% CO2. Exponentially growing cells were used
in all experiments. In addition, genomic DNA from Raji
(human B-cell leukemia), MCF7 (human mammary adeno-
carcinoma), and A431 (human melanoma) cell lines was
purchased from BioCat GmbH (Heidelberg, Germany).
Jurkat and U937 leukemic cells were treated with 5-
aza-2´-deoxycytidine (5-aza-dC), added to a final con-
centration of 1 μM. Cells were prepared at the end of
the 3 day treatment period for analysis of PLA2R1- and
TATA box binding protein (TBP)-specific mRNA.Extraction of genomic DNA and RNA
Genomic DNA was isolated from Jurkat, U937, Bv173, K-
562, OC1-AML3, KG-1A and RPMI 8226 cell lines, per-
ipheral blood samples, and bone marrow aspirates using a
Blood & Cell Culture DNA Mini Kit from Qiagen GmbH
(Hilden, Germany) and following the manufacturer`s
instructions. RNA was isolated after lysis of Jurkat and
U937 cells in TRI Reagent (Sigma-Aldrich, Deisenhofen,
Germany) according to the manufacturer`s instructions.Quantitative RT-PCR analyses
Isolated RNA was converted to cDNA using the GeneAmp
RNA-PCR Kit (PerkinElmer LAS GmbH, Jügesheim,
Germany). For quantitative RT-PCR, portions of the re-
verse transcribed reaction products were then amplified
for identification of PLA2R1 expression in comparison
to those of TBP as a reference gene. Real-time RT-PCR
was performed using Rotor-Gene Q (Qiagen GmbH)
and Rotor Gene SYBR Green PCR kit according to man-
ufacturer`s instructions. The applied primer pairs were
5`-CAG AAG AAA GGC AGT TCT GGA TTG-3` and
5`-AAA GCC ACA TCT CTG GCT CTG ATT-3´ for
PLA2R1, giving PCR products with a length of 496 bp,
and 5`-GAA TAT AAT CCC AAG CGG TTT G-3` and
5`-ACT TCA CAT CAC AGC TCC CC-3` for TBP
amplifying products with 226 bp length. The primers
were applied in a final concentration of 0.8 μM. The
conditions for amplification were as follows: 40
courses at 95°C for 5 sec and 58°C for 10 sec. Ampli-
fied products were than analyzed by electrophoresis
on agarose gels.
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PLA2R1 gene
MethPrimer software (http://www.urogene.org/methprimer)
was used to analyze the proximal promoter and down-
stream regions -700 to +1340 bp relative to exon 1 of
PLA2R1 [16], and thereby assess the presence of 5`-CpG
islands in the promoter region.
Bisulfite genomic sequencing
DNA methylation was analyzed using bisulfite-modified
genomic DNA and by subsequent bidirectional sequen-
cing. Aliquots of 500 ng of isolated genomic DNA were
bisulfite modified [17-19] using the EpiTect Bisulfite Kit
(Qiagen GmbH) according to manufacturer`s instructions.
Three fragments expanding from −662 bp to +1275 bp
relative to exon 1 were amplified by nested or semi-nested
PCR. The applied primer pairs were 5`-TTT GTT GGT
TAT TTG AAG GAG GA-3` and 5`-ACC ATC TAC
CCA TCC CAA AA-3` as extrinsic and 5`-TAT ATT
TTA GTT AGG GTT GTT TTA T-3` and 5`-TTC CTA
CCT TTA AAATAA AAA CAA A-3` as intrinsic primers
for fragment 1 of PLA2R1 (−662 bp to −107 bp from
exon 1), giving PCR products with a length of 556 bp; for
fragment 2 (−105 bp to +783 bp from exon 1) 5`-TTT
GTT TTT ATT TTA AAG GTA GGA A-3` and 5`-ACC
CTA TCT CAA AAA ACA AAC AA-3` as extrinsic and
5`-TTT TTG GGA TGG GTA GAT GG-3`and 5`-ACC
TAA CTT AAA AAT CAC TCC TA-3` as intrinsic pri-
mers, giving PCR products with a length of 888 bp; and
for fragment 3 (+761 bp to +1275 bp from exon 1) 5`-
TAG GAG TGA TTT TTA AGT TAG GT-3` and 5`-
CTC TCC TCC CTC TCT TTA CA-3` as extrinsic and
5`-TAG GAG TGA TTT TTA AGT TAG GT-3` and 5`-
CAA CCT TCT AAA TCT CAT ATA TAA-3` as intrinsic
primers in a semi-nested PCR, amplifying products with
515 bp length.
The primers were applied to a final concentration of
0.8 μM. The conditions for amplification were as follows:
15 courses with extrinsic primers at 94°C for 30 sec, 60-
50°C as touch-down for 30 sec and 72°C for 1 min fol-
lowed by 30 courses with intrinsic primers at 94°C for
30 sec, 62-52°C for 30 sec and 72°C for 1 min. Buffers and
reagents were from GeneAmp Kit (PerkinElmer LAS
GmbH). After amplification, PCR products were subjected
to agarose gel electrophoresis to establish the purity of
amplificates. Five ng of PCR products were then prepared
for sequencing using ABI PRISM BigDye Terminator v3.1.
Samples were purified using Agencourt CleanSEQ system
(Beckman/Coulter Company; MS, USA) and sequenced
using 3730 XL ABI/Hitachi. Sequences of bisulfite-treated
genomic DNA were compared with those of untreated
genomic DNA to verify the efficiency of bisulfite treat-
ment. Ratios of cytosine:thymine and guanine:adenine
residues in the forward or reverse sequencing wererespectively calculated to assess the extent of methylation
at different 5`-CpG sites.
Methylation specific-high resolution melting (MS-HRM)
analyses
MS-HRM analyses were carried out to quantify the ex-
tent of methylation in the distinct region −437 bp to
−270 bp from exon 1 of the PLA2R1 gene. These ana-
lyses were carried using Rotor-Gene Q (Qiagen GmbH)
and the EpiTect MS-HRM PCR Kit according to manu-
facturer`s instructions. Bisulfite modified unmethylated
and methylated standard DNA (Qiagen GmbH) were
mixed giving samples with 0%, 10%, 20%, 30%, 50%, and
100% methylation ratios for calibration. A standard
curve with known methylation ratios was included in
each run. PCR was performed in 12.5 volumes. The ap-
plied primer pairs were 5`-GGG GTA AGG AAG GTG
GAG AT-3` and 5`-ACA AAC CAC CTA AAT TCT
AAT AAA CAC-3` giving PCR products with a length of
168 bp. The primers were applied at a final concentra-
tion of 0.8 μM. The conditions of amplification were as
follows: 40 courses at 95°C for 10 seconds, 58°C for
30 seconds and 72°C for 15 sec. Immediately after PCR,
products were analyzed by high resolution melting ana-
lysis with fluorescence measured during the linear
temperature transition from 50-95°C at 0.01°C/second.
Data analysis
Data were analyzed by two-tailed and unpaired Stu-
dent`s t-test. Differences were considered significant at
p < 0.05. Pearson Product Moment Correlation was ap-
plied to analyze the HRM values in relation to IPSS clas-
sification of MDS patients.
Results
Re-expression of PLA2R1 in human Jurkat and U937
leukemia cells
Under control conditions, in Jurkat and U937 cells no
PLA2R1-mRNA were detectable after RT-PCR and agar-
ose gel electrophoresis (Figure 1A). Furthermore, no
amplification occurred using real-time RT-PCR (the amp-
lification efficiency was below 0.50). Simultaneously, the
methylation of the PLA2R1 gene averaged 100% in both
cell lines analyzed by MS-HRM analyses (Figure 1B) and
sequencing (Figure 2B) of bisulfite-modified genomic
DNA. After exposure of cells to 5-aza-dC, however, sig-
nificant PLA2R1 transcript levels were detectable both in
the agarose gel electrophoresis (Figure 1A) and real-time
RT-PCR (in Jurkat cells the ratio was 1.61x10(−E3) ±
0.36x10(−E3) with an efficiency of 1.56 and in U937 cells
the ratio between PLA2R1/TBP mRNA levels averaged
1.21x10(−E4) ± 0.48x10(−E4) with an amplification effi-
ciency of 1.74). In parallel, the PLA2R1 gene methylation
AB
Figure 1 Effects of 5-aza-2´-deoxycytidine (5-aza-dC) treatment on PLA2R1 methylation (A) and PLA2R1 expression (B) in Jurkat and
U937 leukemic cells. After exposure of cells to vehicle or 1 μM 5-aza-dC for 72 h mRNA and DNA were isolated. (A) MS-HRM analyses of PLA2R1
methylations with a standard curve of 0%, 25%, 50%, 75%, and 100% methylation (in black lines) without (in blue) and with exposure (in red) of
cells to the DNA demethylating agent, 5-aza-dC. Difference plots normalized to the 0%-methylated standard DNA sample are shown. (B) Agarose
gel electrophoresis of RT-PCR amplificates of PLA2R1 in comparison to TBP-specific mRNA in Jurkat and U937 cells, with and without exposure to
5-aza-dC. Lanes 1 and 2; control cells (without addition of 5-aza-dC), lanes 3 and 4 represent cells treated respectively with 5-aza-dC, L; ladder.
Analyses were performed in duplicates and results are representative of three independent experiments.
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U937 cells using MS-HRM analyses (Figure 1B).
PLA2R1 gene 5`-CpG islands
Four distinct 5`-CpG islands were identified by Methpri-
mer software-based analysis of the proximal promoter
and down-stream regions covering -700 to +1340 bp
from exon 1 of the PLA2-R1 gene. The first island was
located at −357 to −243 bp, the second at +38 to
+459 bp, the third at +512 to +668 bp, and the fourth at
+837 to +991 bp from exon 1 (Figure 2A).
Methylation of the PLA2R1 gene in healthy individuals,
leukemic cell lines and leukemic patients
Among healthy controls (N = 10), the methylation of 5`-
CpG sites 2 (according to our nomenclature; -533 bp from
exon 1), 3 (−522 bp), and 81 (+602 bp) to 108 (+1216 bp)
was between 20% and 100%, whereas the 5`-CpG site 1
(−584 bp) and sites 4 to 80 (−473 bp to +586 bp from
exon 1, respectively) were unmethylated (Figure 2B).
In contrast, in 15 patients with different types of
leukemia (P1 to P3 and P5 to P16, Additional file 1:
Table S1) a hypermethylation of the 5`-CpG sites 1 and
4 to 80 was found (Figure 2B). In one patient with AML,
FAB M4 (P4), however, there was no detectable hyper-
methylation of this region (Additional file 1: Table S1).In U937 and Jurkat cell lines a strong methylation of
the 5`-CpG sites 1 and 4 to 80 in the PLA2R1 gene was
also identified (Figure 2B).
PLA2R1 methylation quantified using MS-HRM analysis
Next, we used MS-HRM analyses to quantify PLA2R1
methylation at 5`-CpG sites identified with most signifi-
cant differences in methylation between healthy control
subjects and leukemic patients. On the basis of sequencing
data we selected a region between -437 to −270 bp relative
to exon 1 of the PLA2R1 gene (black line in Figure 2B)
which covers the 5`-CpG sites 6–14 (according to our no-
menclature; -415 bp to −298 bp from exon 1) and localizes
in the proximal promoter of PLA2R1. This region showed
the most significant differences in methylation between 10
healthy control subjects and 16 leukemic patients.
In Figure 3, examples of MS-HRM data from leukemic
patients compared to normal subjects and in Table 1, MS-
HRM data from analyzed cell lines are shown. The ana-
lysis of DNA from blood samples from 32 patients with
leukemia and 52 normal individuals indicated respective
rates of methylation of 28.9 ± 17.8% and 6.9 ± 2.5%
(Figure 4, Table 2, and Additional file 1: Table S1). Patient
P4, in who sequencing analysis indicated undetectable
PLA2R1 methylation in the region −473 bp and +586 bp,
was found to have a 7% PLA2R1 methylation by MS-
AB
Figure 2 5`-CpG islands and methylation of proximal promoter and down-stream regions of the PLA2R1 gene determined by
sequencing of bisulfite modified genomic DNA. (A) PLA2R1 promoter and down-stream regions covering −700 to +1340 bp relative to exon 1
containing four 5`-CpG islands labelled in grey are shown; island-1, 115 bp length (−357 to −243 bp); island-2, 422 bp (+38 to +459); island-3,
157 bp (+512 to +668 bp), and island-4, 155 bp (+837 to +991 bp). Criteria used for 5`-CpG island prediction: island size >100 bp, GC percent
>50.0, Minimum observed/expected >0.6. Horizontal black bar depicts the region expanding from −437 to −270 bp relative to exon 1 whose
methylation was quantified using MS-HRM analysis. (B) Extents of methylation of distinct 5`-CpG sites in the PLA2R1 promoter and down-stream
region of U937 and Jurkat cells as well as PLA2R1 methylations in DNA from blood of 10 healthy individuals and 16 leukemic patients (means ±
SDs) determined by sequencing of bisulfite modified genomic DNA. Horizontal black bars show 5`-CpG sites analyzed by MS-HRM analyses.
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tient (P17, AML, FAB M0) showed no elevation in
PLA2R1 methylation (3% methylation degree, Additional
file 1: Table S1). Among healthy subjects, there was one
individual who showed a 21% level of methylation for the
PLA2R1 gene (N19, Additional file 1: Table S1).Among the group of MDS patients, the melt curves of
PLA2R1 amplificates from bone marrow aspirates differed
considerably with increased IPSS classification. In particu-
lar, the level of PLA2R1 methylation increased with the
disease stage (Additional file 4: Figure S1). Consistent with
this, MS-HRM values of PLA2R1 methylation correlated
 deg.










































Figure 3 Methylation of the PLA2R1 gene in DNA samples from blood of patients with leukemia in comparison to normal individuals.
MS-HRM analyses using RotorGene Q of amplified PLA2R1 sequences covering 5`-CpG sites 6–14 (−437 bp to −270 bp from exon 1) after isolation
and subsequent bisulfite modification of genomic DNA from normal subjects (N1-N10, black), and patients with leukemia (P1 to P6, P9, and P10;
in colors, individual data are shown in Additional file 1: Table S1). Difference plots normalized to the 0%-methylated standard DNA sample and a
standard curve with 0%, 20%, 30%, 40%, 60%, and 100% methylation ratios in black dotted lines are shown.
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PLA2R1 methylation was below 19% in all of low-risk
patients, the MS-HRM values were only partially below
this degree in intermediate-1-risk patients and signifi-
cantly higher in the groups of intermediate-2 and high-
risk patients (Figure 5 and Additional file 2: Table S2).
PLA2R1 methylations in MDS and AML patients during
azacitidine treatment
In the group of 18 high-risk MDS and AML patients
treated with azacitidine as methyltransferase inhibitor,
six patients had PLA2R1 methylation degrees above 9%Table 1 PLA2R1 gene methylations in different human cell lin
Cell lines classification
Jurkat human T cell leukemia
U937 human monocytic leukem
Bv173 human B-cell precursor leu
Raji human B cell leukemia
OC1-AML3 human akute myeloid leuk
KG-1A human acute myeloid leuk
K-562 human CML in blast crisis
MCF7 human mammary adenoc
A431 human melanoma
RPMI-8226 human multiple myeloma
The degree of methylation was measured using MS-HRM analysis of bisulfite-modif(Additional file 3: Table S3). In course of treatment with
azacitidine, three of these patients (P73, P87 and P88)
showed decreased methylation levels and can be classi-
fied as responders. In contrast, one patient (P86)
showed increased methylation level in blood leukocytes
after treatment in comparison to those at the beginning
of treatment. This patient together with two patients
whose methylation degrees were unchanged after azaci-
tidine treatment, can be classified as non-responders
(Additional file 3: Table S3). Among patients with
PLA2R1 methylation of 9% or below, four patients
































Figure 4 Box-plots of PLA2R1 methylations in DNA from blood
of healthy individuals (Controls, N = 52) and leukemic patients
(Leukemia, N = 32). MS-HRM analyses of amplified PLA2R1
sequences (covering 5`-CpG sites 6–14, -437 bp to −270 bp from
exon 1) after isolation and subsequent bisulfite modification of
genomic DNA from blood samples were performed using
RotorGene Q (Qiagen). Boxes within the plots represent the 25-75th
percentiles. Median values are depicted as solid lines. Circles indicate
outlier values outside of the 10th and 90th percentiles.
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Figure 5 Methylation of the PLA2R1 gene in bone marrow
aspirates of MDS patients in dependence on IPSS classification.
After isolation and subsequent bisulfite modification of genomic
DNA from bone marrow aspirates of MDS patients (N = 38)
methylations of amplified PLA2R1 sequences covering 5`-CpG sites
6–14 (−437 bp to −270 bp from exon 1) were analyzed using MS-
HRM (HRM,%). Low, low risk; int-1, intermediate-1-risk; int-2,
intermediate-2-risk; and high, high-risk classifications.
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azacitidine treatment (Additional file 3: Table S3).
Furthermore, we analyzed the PLA2R1 methylation in a
patient with AML (FAB M2) following allogeneic HSCT,
who had minimal residual disease (MRD) and underwent
pre-emptive treatment with azacitidine to avoid haemato-
logical relapse (Additional file 5: Table S4). Methylation
of the selected PLA2R1 region was below 9% at the start
and end of the first course of treatment; normal melt
curves of amplicons were also found (Figure 6A). At the
beginning of second treatment course, a moderate in-
crease of PLA2R1 methylation at 12% was measured,
which decreased to 9% at the end of the treatment course
(Additional file 5: Table S4). Melt curve analysis indicatedTable 2 Averaged PLA2R1 methylations in DNA from
blood of normal individuals (Control, N = 52) and
leukemic patients (Leukemia, N = 32) analysed by MS-
HRM
Group N Methylation (mean ± SD)
Control 52 6.9% ± 2.5%
Leukemia 32 28.9% ± 17.8% **
** p = <0.001 in comparison to controls
In the control group, one individual exhibited a PLA2R1 methylation of 21%
and in the leukemic group, two patients had methylations of 7% and 3%
(patient details see in Additional file 1: TableS1). The 95th percentile value
usable as cut-off averaged 9%.a minor fraction of completely methylated PLA2R1 at the
beginning of this treatment course, which completely
disappeared after treatment (Figure 6B). Twenty-two
days later at the beginning of course 3, the methylation
of the tested PLA2R1 region in DNA from blood
averaged 50% (Figure 6C and 6D) and 9% blasts were
detectable (Additional file 5: Table S4). A similar distri-
bution of unmethylated and methylated DNA was mea-
sured in a bone marrow DNA sample using MS-HRM
and melt curve analyses at the same time point (data
not shown). At the end of course 3 with azacitidine
treatment, the methylation of PLA2R1 in DNA from
blood decreased, but remained at 35% (Figure 6D). At
the same time the MRD, as detected by CD34-donor chi-
merism, had further increased suggesting no sufficient
response to pre-emptive azacitidine treatment. Shortly
later the patient developed overt haematological relapse.
Discussion
This study establishes for the first time that epigenetic
mechanisms are involved in the regulation of PLA2R1
expression in leukemic cells. On the basis of two previ-
ously published studies the observed epigenetic down-
regulation of PLA2R1 in leukemic cells may have
pathophysiological relevance. First, it was shown that
secreted phospholipases A2 (types IIA and IB) induce
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Figure 6 Methylation of PLA2R1 in DNA from the blood of a patient with AML after hematopoietic stem cell transplantation and
minimal residual disease during three courses with azacitidine treatment. (A) Melt curve analyses of bisulfite-modified genomic DNA at the
start (blue) and end (orange) of the first course of treatment, (B) at the start (blue) and end (orange) of the second course of treatment, and (C)
at the start (blue) and end (orange) of the third course of treatment. (D) MS-HRM analyses at the start (blue) and end (orange) of the third course
of azacitidine treatment. Melt curves of unmethylated (0%) and methylated (100%) standard DNA samples (A-C) and a standard curve with 0%,
5%, 10%, 20%, 30%, 50%, 75%, and 100% methylation ratios (D) are shown in black. (A-C); fluorescence dF/dT and (D) difference plot normalized
minus 0. Analyses were performed in duplicates and results are representative of three independent measurements.
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[20]. Second, the inhibition of the cell growth induced by
secreted phospholipase A2 (type IIA) overexpression is
reverted in PLA2R1-depleted cells [21]. Using a retroviral
short hairpin RNA library targeting about 8,000 human
genes the authors of the latter study identified the
PLA2R1, along with four other genes, to play a crucial role
in senescent primary human fibroblasts. Moreover, they
demonstrated that the effect of PLA2R1 down-regulation
is not limited to primary human fibroblasts, but is also
present in other human cells such primary human mam-
mary epithelial cells [21].
The above findings serve to emphasize the possible role
of PLA2R1 gene hypermethylation in human blood cells
of leukemic patients. The process of senescence is seen as
a tumor suppression mechanism preventing malignanttransformation. Inversely, an escape from senescence can
lead to a progression of malignancy [21-24]. Therefore, in
future studies it will be interesting to define cell types, in
which the PLA2R1 gene is hypermethylated and whether
in these cells the hypermethylation is connected with
PLA2R1 silencing.
Additionally, the study of MDS patients demonstrates
that PLA2R1 gene methylation correlates with IPSS clas-
sification and may be useful as an additional biomarker
for risk stratification. Our data confirm previous work
demonstrating increased methylation with MDS disease
stage, suggesting that hypermethylation of certain tumor
suppressor genes is a mechanism of disease evolution in
leukemogenesis [25].
A further question arising from our study is whether the
extent of PLA2R1 methylation can be used as a biomarker
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indicator of a potential response to treatment could be, for
example, particularly useful when initiating treatment with
methyltransferase inhibitors such as azacitidine. The data
received in a first group of patient who were treated with
azacitidine show that a significantly decrease in extent of
PLA2R1 methylation after one course of 5-aza-dC treat-
ment can be measured in a subgroup of patients, whereas
in other patients the methylation was unchanged or even
increased. A similar effect of demethylating treatment on
gene methylation was described in case of phosphoinositide-
phospholipase C-beta1 [26]. These suggest that the PLA2R1
gene may function as a possible target to monitor the effi-
ciency of demethylating therapy. In addition, we show in a
patient with AML after HSCT, how melt curve analyses of
amplified PLA2R1 sequences may indicate a recurrence or
progression of the disease. For this reason further studies
seem warranted to follow the effects of demethylating
therapies on PLA2R1 methylation in a larger number of
leukemic patients.
In addition to diagnosis and control of methylation-
related therapies the observation that inhibition of DNA
methylation can restore the PLA2R1 expression may have
important implications for development of novel strategies
to treat leukemia. There is growing evidence that anti-
oncogenic and pro-apoptotic properties of sPLA2 isozymes
may have importance for defective pathways of apoptosis
in tumorigenesis [27-31]. However, little is known about
the biological function and regulation of PLA2R1 expres-
sion as potential binding site of sPLA2s. In PLA2R1-
deficient mice lower blood levels of TNF-α- and IL-1β
were found after lipopolysaccharide application which was
connected with a relative resistance to lipopolysaccharide-
induced lethality. Therefore, a pro-inflammatory function
was postulated for PLA2R1 [32]. Furthermore, an endo-
cytosis of PLA2R1 was described similar to the LDL-
receptor associated with lysosomal degradation of bound
sPLA2s suggesting that the receptor plays a crucial role in
the regulation of sPLA2 activities during inflammation
[10,33]. On the basis of the finding that the PLA2R1 can
be restored in Jurkat and U937 cells by demethylating
treatment, new opportunities are opened to analyze the
effects of the receptor re-expression on senescence and
apoptosis. These studies may be a source for developing
alternative strategies for leukemic treatment using the
PLA2R1 as target.
Conclusions
The data of this study indicate that in Jurkat and U937
leukemic cells the inhibition of methylation by 5-aza-dC re-
expresses PLA2R1 and that in MDS and leukemic patients,
in contrast to healthy individuals, PLA2R1 promoter
sequences are hypermethylated. This suggests that, in
addition to chromosome aberrations and gene mutations,aberrant methylation plays a crucial role in MDS and its
evolution to AML. The study also shows that the determin-
ation of PLA2R1 methylation by melt curve and MS-HRM
analyses may be useful for risk stratification of MDS and
AML patients and therapeutic control of leukemia using
methylation inhibitors.Additional files
Additional file 1: Table S1. Characteristics of patients analyzed for PLA2R1
methylation using MS-HRM analysis of bisulfite-modified genomic DNA.
Additional file 2: Table S2. Characteristics of MDS patients with
different IPSS classifications. The degree of PLA2R1 methylation shown
was measured using MS-HRM analysis of bisulfite-modified genomic DNA
from bone marrow aspirates. CMML-1, chronic myelomonocytic leukemia;
RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS,
refractory cytopenia with multilineage dysplasia and ringed sideroblasts;
RAEB, refractory anemia with excess blasts; RCUD, refractory cytopenia
with unilineage dysplasia; RAEB-t, refractory anemia with excess blasts in
transformation; sAML, secondary acute myeloid leukemia.
Additional file 3: Table S3. Characteristics of patients treated with
azacitidine. The degree of PLA2R1 methylation shown was measured
using MS-HRM analysis of bisulfite-modified genomic DNA from blood
samples. RCMD, refractory cytopenia with multilineage dysplasia; RAEB,
refractory anemia with excess blasts; RAEB-t, refractory anemia with
excess blasts in transformation.
Additional file 4: Figure S1. Melt curve analyses of bisulfite-modified and
amplified PLA2R1 gene sequences in bone marrow aspirates of MDS
patients. After isolation and subsequent bisulfite modification of genomic
DNA from bone marrow aspirates melt properties of amplified PLA2R1
sequences covering 5`-CpG sites 6–14 (−437 bp to −270 bp from exon 1)
were analyzed using RotorGene Q. P34; a 74 years old male patient with
RCMD and low-risk according to IPSS classification, P57; a 69 years old male
patient with RAEB-2 and intermediate-1-risk, P66; a 69 years old female
patient with RAEB-2 and intermediate-2-risk, and P69; a 56 years old male
patient with AML and high-risk classification. Individual data of MDS patients
are summarized in Additional file 2: Table S2. Melt curves of amplified
genomic DNA from MDS patients (in colors) and those of unmethylated
(0%) and methylated (100%) standard DNA samples (in black) are shown.
Fluorescence dF/dT were measured. Analyses were performed in duplicates
and results are representative of three independent measurements.
Additional file 5: Table S4. MS-HRM analyses of bisulfite-modified
genomic DNA isolated from peripheral blood samples of a 58 years old
female patient with minimal residual disease. After treatment of AML,
FAB M2, by allogeneic hematopoietic stem cell transplantation three
years ago the patient underwent a pre-emptive treatment with
azacitidine to avoid haematological relapse. Amounts of leukocytes,
blasts, and PLA2R1 methylation degrees during treatment measured
using MS-HRM analysis are summerized. n; normal melt curve without
methylated DNA fraction, p; pathological melt curve with methylated
DNA fraction in addition to unmethylated DNA fraction.Abbreviations
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